Physician profile
Ashley Modugno
NPI 1558973610
$1,176.40
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $193 · 2023: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.88 | 2021-2023 | |
| Glaxosmithkline, LLC. | $127.74 | 2022-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $101.41 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $79.58 | 2022-2023 | Mounjaro, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.18 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.62 | 2021-2023 | Synjardy, Jardiance, Tradjenta |
| Gilead Sciences, INC. | $48.07 | 2022-2023 | |
| Novo Nordisk INC | $32.29 | 2023 | Ozempic, Rybelsus |
| Amgen INC. | $29.71 | 2022-2023 | Otezla, Repatha |
| Neurocrine Biosciences, INC. | $24.99 | 2023 | Ingrezza |
| Exact Sciences Corporation | $24.98 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.19 | 2022 | |
| Corcept Therapeutics | $18.98 | 2023 | Korlym |
| Otsuka America Pharmaceutical, INC. | $13.78 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Modugno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.